13:59:29 EST Wed 18 Nov 2026
Enter Symbol
or Name
USA
CA



nDatalyze Corp.
Symbol NDAT
Shares Issued 41,327,425
Close 2026-11-16 C$ 0.03
Market Cap C$ 1,239,823
Recent Sedar+ Documents

ORIGINAL: nDatalyze Corp. Announces appointment of a new President and Director, the resignation of a current Director, and Stock Option Grants

2026-11-18 07:15 ET - News Release

(via TheNewswire)

nDatalyze Corp.
 

Calgary, Alberta – TheNewswire - November 18, 2026. nDatalyze Corp. (CSE: NDAT. OTC: NDATF) (“NDAT” or the “Corporation”) announces that, effective immediately, D’Arcy Funfer will become the Corporation’s President and CEO. Jim Durward, the outgoing President and CEO, will stay on as Chairman of the Board of Directors. Mr. Funfer will also succeed Gordon Crawford as a Director and the Corporation thanks Mr. Crawford for his service and wishes him well in his endeavors.

 

Over the past six months, the corporation has been quietly developing its advanced athletic assessment platform (“EpitomePD”) and can now focus on the commercialization phase.  EpitomePD can address multiple sports and other high human performance markets, with the initial focus being Hockey. The EpitomePD website is at https://www.epitomepd.com/

 

Mr. Funfer, the new President, states: “ I’m grateful to nDatalyze’s Board of Directors for entrusting me with the role of President and CEO. What excites me about EpitomePD is its goal of helping individual amateur hockey players better understand how they are built so they can develop smarter. By bringing together insights into a player’s mindset, genetic predispositions, and environmental development, the platform helps players, families, and coaches make more informed training decisions. I’m honoured to lead EpitomePD as we bring this approach to more players and hockey organizations across North America and beyond.”

 

The Corporation has granted an aggregate of 3,700,000 stock options to its directors and officers, pursuant to the Corporation’s stock option plan, at an exercise price of $0.05 per common share

and expiring two years from the date of grant. The stock options are subject to a customary four month hold period from the date of grant.

 

About nDatalyze Corp.

nDatalyze Corp. is a technology company focused on developing health and performance-related solutions through the application of artificial intelligence and biometric data analytics, including the Epitome sports performance platform (https://www.epitomepd.com)

For Further Information, please contact:

D’Arcy Funfer, President and CEO

Email: dsfunfer@gmail.com

Tel: (403) 828-2200

 

For technical matters: Jim Durward, Chairman of the Board of Directors

Email: jimd@ndatalyze.com

Tel: (403) 689-3901

 

nDatalyze Website: https://www.ndatalyze.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward-looking statements, including statements regarding the return of escrowed subscription proceeds, the reinstatement of trading of the Company’s common shares on the Canadian Securities Exchange and the commercialization of the Epitome platform. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Although the Corporation believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

Copyright (c) 2026 TheNewswire - All rights reserved.

© 2026 Canjex Publishing Ltd. All rights reserved.